Docosahexaenoic acid induces apoptosis in primary chronic lymphocytic leukemia cells | Zendy

Romain Guièze | Zendy; Emmanuel Gyan | Zendy; Olivier Tournilhac | Zendy; Christelle Halty | Zendy; Richard VeyratMasson | Zendy; Saïda Akil | Zendy; Marc Berger | Zendy; Olivier Hérault | Zendy; Mary Callanan | Zendy; JacquesOlivier Bay | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Docosahexaenoic acid induces apoptosis in primary chronic lymphocytic leukemia cells

Author(s) -

Romain Guièze,

Emmanuel Gyan,

Olivier Tournilhac,

Christelle Halty,

Richard VeyratMasson,

Saïda Akil,

Marc Berger,

Olivier Hérault,

Mary Callanan,

JacquesOlivier Bay

Publication year - 2015

Publication title -

hematology reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.239

H-Index - 12

ISSN - 2038-8330

DOI - 10.4081/hr.2015.6043

Subject(s) - docosahexaenoic acid , apoptosis , chronic lymphocytic leukemia , in vitro , medicine , in vivo , leukemia , potency , cancer , pharmacology , cancer cell , cancer research , ic50 , oleic acid , fatty acid , immunology , biochemistry , polyunsaturated fatty acid , biology , microbiology and biotechnology

Chronic lymphocytic leukemia is an indolent disorder with an increased infectious risk remaining one of the main causes of death. Development of therapies with higher safety profile is thus a challenging issue. Docosahexaenoic acid (DHA, 22:6) is an omega-3 fatty acid, a natural compound of normal cells, and has been shown to display antitumor potency in cancer. We evaluated the potential in vitro effect of DHA in primary CLL cells. DHA induces high level of in vitro apoptosis compared to oleic acid in a dose-dependent and time-dependent manner. Estimation of IC50 was only of 4.813 μM, which appears lower than those reported in solid cancers. DHA is highly active on CLL cells in vitro. This observation provides a rationale for further studies aiming to understand its mechanisms of action and its potent in vivo activity

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research